Core Insights - MediWound Ltd. is presenting 10 scientific abstracts at the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, focusing on EscharEx's mechanism of action and its advantages over SANTYL in treating chronic wounds [1][2][4] Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair, with its FDA-approved product NexoBrid for thermal burns [6][7] Product Information - EscharEx is a bromelain-based enzymatic therapy designed for the debridement of chronic wounds, showing a favorable safety profile and effective wound bed preparation in multiple Phase II trials [5][6] - The therapy has demonstrated the ability to remove non-viable tissue, promote granulation, and reduce bioburden and biofilm, targeting a substantial global market opportunity [5][7] Clinical Development - The ongoing VALUE Phase III study is enrolling patients with venous leg ulcers (VLUs), building on positive results from three completed Phase II studies that confirmed EscharEx's efficacy and safety [4][5] - A Phase II/III study in diabetic foot ulcers (DFUs) is in preparation, with new data supporting the planned clinical trial strategy [2][5] Conference Highlights - Key presentations at WHS and SAWC will include new in vitro data on EscharEx's multitargeted proteolytic activity, case studies in advanced DFUs and VLUs, and updates on the VALUE Phase III study design and enrollment progress [6][8]

Core Viewpoint - Madrigal (MDGL) reported a quarterly loss of $2.71 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.12, indicating a positive earnings surprise of 34.22% [1] Financial Performance - The company posted revenues of $103.32 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.69%, compared to zero revenues a year ago [2] - Over the last four quarters, Madrigal has exceeded consensus EPS estimates three times [2] Stock Performance and Outlook - Madrigal shares have increased by approximately 0.3% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.17 on revenues of $106.02 million, and for the current fiscal year, it is -$12 on revenues of $536.23 million [7] Industry Context - The Medical - Drugs industry, to which Madrigal belongs, is currently in the top 50% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Madrigal's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to ____________________ OR ☐ SHELL COMPANY REPORT P ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to____________________ OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20‑F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ SHELL COMPANY REPORT PURS ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20‑F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...